Twelve consumer advocates have taken seats as new members on the National Cancer Institute (NCI) Director's Consumer Liaison Group (DCLG), joining three returning members ...
January 21, 2005 (Press Release) --
Twelve consumer advocates have taken seats as new members on the National Cancer Institute (NCI) Director's Consumer Liaison Group (DCLG), joining three returning members, as the NCI increases its initiatives to reach out to the cancer community.
Announcing the new DCLG, NCI Director Andrew C. von Eschenbach, M.D., said: "NCI continues to broaden and deepen our communications efforts with the cancer advocacy community and I am very encouraged that we now have so many new perspectives. As we work toward our challenge goal of eliminating the suffering and death due to cancer by 2015, it is important that NCI shares its progress with everyone who stands to benefit, and responds to any concerns the cancer community may have. The DCLG will play a vital role in this communication."
The 12 new and three returning members comprise a group that has had personal or professional experience with cancer in a broad spectrum of disease sites, including kidney, ovarian, breast, and prostate cancers and leukemia and lymphoma. The members are active in survivor and community groups and represent underserved populations.
Launched in 1997, the DCLG -- a federally chartered committee -- was the first all-consumer advisory board at the National Institutes of Health (NIH). The DCLG's 15 members advise the NCI director about a wide variety of issues, programs, and research priorities from the perspective of people whose lives are affected by cancer. Since the establishment of the DCLG, other NIH institutes and centers have created consumer advisory boards or councils to reach out to the public affected by their research. Because NIH research is funded by taxpayer money and ultimately benefits the public, the institutes and centers seek public input into many aspects of their operations and activities.
continue ...
For more information about the Director's Consumer Liaison Group, go to http://la.cancer.gov/dclg.html.
For more information about cancer, visit the NCI Web site at http://www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
Announcing the new DCLG, NCI Director Andrew C. von Eschenbach, M.D., said: "NCI continues to broaden and deepen our communications efforts with the cancer advocacy community and I am very encouraged that we now have so many new perspectives. As we work toward our challenge goal of eliminating the suffering and death due to cancer by 2015, it is important that NCI shares its progress with everyone who stands to benefit, and responds to any concerns the cancer community may have. The DCLG will play a vital role in this communication."
The 12 new and three returning members comprise a group that has had personal or professional experience with cancer in a broad spectrum of disease sites, including kidney, ovarian, breast, and prostate cancers and leukemia and lymphoma. The members are active in survivor and community groups and represent underserved populations.
Launched in 1997, the DCLG -- a federally chartered committee -- was the first all-consumer advisory board at the National Institutes of Health (NIH). The DCLG's 15 members advise the NCI director about a wide variety of issues, programs, and research priorities from the perspective of people whose lives are affected by cancer. Since the establishment of the DCLG, other NIH institutes and centers have created consumer advisory boards or councils to reach out to the public affected by their research. Because NIH research is funded by taxpayer money and ultimately benefits the public, the institutes and centers seek public input into many aspects of their operations and activities.
continue ...
For more information about the Director's Consumer Liaison Group, go to http://la.cancer.gov/dclg.html.
For more information about cancer, visit the NCI Web site at http://www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
Email
Print
SPAM
LEAVE A COMMENT
